Acquisitions, Mergers & PartnershipsCareers in AMMedical AMPersonalized Medicine

CurifyLabs acquires intellectual property from Mehta Heino

Petri Heino, CTO of Mehta Heino, has also joined CurifyLabs as Lead Hardware Engineer

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Finnish health technology pioneer CurifyLabs, has acquired significant intellectual property (IP) from Mehta Heino Industries Oy, a Finnish 3D printing hardware development company. The acquisition marks a pivotal moment in CurifyLabs’ capability to offer unparalleled 3D printing solutions for producing personalized medicines in the pharma industry.

“The acquisition of Mehta Heino’s IP and other assets is a game-changer for us. Their innovative approach to 3D printing technology perfectly aligns with our vision enabling wider adoption of personalized treatments. This acquisition is not merely about growing our portfolio; it’s about leading the industry into a new era,” said Charlotta Topelius, Co-founder and CEO of CurifyLabs.

CurifyLabs acquires intellectual property from Mehta Heino. Petri Heino, CTO of Mehta Heino, has joined CurifyLabs as Lead Hardware Engineer.
Petri Heino.

In addition to the IP acquisition, Petri Heino, CTO of Mehta Heino, has joined CurifyLabs as Lead Hardware Engineer. “CurifyLabs presents an extraordinary opportunity to push the boundaries of what is possible in 3D printing and advanced robotics in healthcare. Me and my Co-founder Santosh Mehta spent eight years developing our technology and we are thrilled to see our IP contribute to groundbreaking advancements for the benefit of vulnerable patient populations that need personalized treatments,” said Petri Heino.

CurifyLabs’ Pharma Kit solution, which combines innovative printable Pharma Inks with 3D printing technology and quality control, provides an automated solution for producing personalized medicine in hospitals and compounding pharmacies. The solution eliminates the manual process and makes compounding more accessible, cost-effective, safe, and scalable.

“For pharmacies, speed, seamless workflows, and regulatory compliance are essential. We enable this with our unique personalized medicine manufacturing solution. With Mehta Heino’s IP, we’re taking our commitment to effective solutions to the next level. Our combined expertise will result in more efficient manufacturing solutions, facilitating the wider adoption of personalized medicine and enhanced care for patients with individual needs,” said Niklas Sandler, Co-founder and CTO at CurifyLabs.

“We must pay special attention to pediatric populations where personalized medicines are crucial. The IP acquisition and adding Petri to our team enhance our ability to do just that,” said Charlotta Topelius.

Research
Composites AM 2024

746 composites AM companies individually surveyed and studied. Core composites AM market generated over $785 million in 2023. Market expected to grow to $7.8 billion by 2033 at 25.8% CAGR. This new...

Edward Wakefield

Edward is a freelance writer and additive manufacturing enthusiast looking to make AM more accessible and understandable.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Save
Accept all Services

Newsletter

Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.